BioSenic S.A.
Research BioSenic S.A. (BIOS) on Bullrun: market cap EUR 1.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOS
- ExchangeBR
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.31M
- Financial periodFY2023
- RevenueEUR 0
- Net income-EUR 28.78M
- Free cash flow-EUR 3.47M
Valuation Snapshot
latest market cap is EUR 1.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2023 | EUR 0 | -EUR 28.78M | -EUR 3.47M | n/a | -0.21 | EUR 117.00K | EUR 28.16M | -EUR 22.91M |
| FY2022 | EUR 0 | -EUR 2.04M | -EUR 1.92M | n/a | -0.02 | EUR 1.85M | EUR 23.79M | EUR 3.53M |
| FY2021 | EUR 0 | -EUR 984.00K | -EUR 1.07M | n/a | -14.89 | EUR 759.00K | EUR 3.50M | -EUR 2.67M |
| FY2020 | EUR 1.00M | -EUR 11.94M | -EUR 16.16M | n/a | n/a | EUR 14.65M | n/a | EUR 3.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 1.31M | n/a | n/a | n/a |
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioSenic S.A.'s market cap?
BioSenic S.A.'s market capitalization is EUR 1.31M.
What does BioSenic S.A. do?
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.